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Objectives: The present study was designed to investigate further the efﬁcacy and safety of
zoledronic acid (ZOL) and propranolol (PRO) as monotherapy and combination therapy in a
rat  model of postmenopausal osteoporosis.
Methods: Female Wistar rats were ovariectomized (OVX) or sham-operated at 3 months of
age. Twelve weeks post-surgery, rats were randomized into six groups: (1) sham + vehicle;
(2)  OVX + vehicle; (3) OVX + ZOL (100 g/kg, i.v. single dose); (4) OVX + ZOL (50 g/kg, i.v. sin-
gle  dose); (5) OVX + PRO (0.1 mg/kg, s.c. 5 days per week); (6) OVX + ZOL (50 g/kg, i.v. single
dose) + PRO (0.1 mg/kg, s.c. 5 days per week) for 12 weeks. After treatment, femurs were
tested for bone density, porosity and trabecular micro-architecture. Biochemical markers in
serum and urine were also determined.
Results: Combined treatment with ZOL plus PRO corrected the decrease in serum calcium
and  increase in serum alkaline phosphatase and tartarate resistant acid phosphatase level
better than single-drug therapy using ZOL or PRO. Moreover, combined treatment with ZOL
plus PRO corrected the increase in urine calcium, phosphorous and creatinine level better
than single-drug therapy using ZOL or PRO. Combination therapy using ZOL plus PRO also
preserved the trabecular micro-architecture and cortical bone porosity.
Conclusion: These data suggest that combined treatment with ZOL plus PRO could be a moreeffective approach for treating severe osteoporosis in humans.
© 2014 Elsevier Editora Ltda. All rights reserved.∗ Corresponding author.
E-mail: deepak kumarkhajuria@yahoo.co.in (D.K. Khajuria).
ttp://dx.doi.org/10.1016/j.rbre.2014.09.008
255-5021/© 2014 Elsevier Editora Ltda. All rights reserved.
104  r e v b r a s r e u m a t o l . 2 0 1 5;5 5(2):103–112
Efeitos  combinados  do  ácido  zoledrônico  e  do  propranolol  sobre  a
densidade  óssea  e  marcadores  bioquímicos  de  remodelac¸ão óssea  em
ratas  osteopênicas  submetidas  à  ovariectomia
Palavras-chave:
Estudo com ratos
Osteoporose pós-menopáusica
Ácido zoledrônico
Propranolol
r  e  s  u  m  o
Objetivos: Este estudo foi desenvolvido para investigar a eﬁcácia e a seguranc¸a do ácido
zoledrônico (ZOL) e do propranolol (PRO) como monoterapia e terapia combinada em um
modelo de rato com osteoporose pós-menopáusica.
Métodos: Ratas Wistar fêmeas foram ovariectomizadas (OVX) ou submetidas à cirurgia sim-
ulada (placebo) aos três meses de idade. Doze semanas depois da cirurgia, as ratas foram
divididas em seis grupos: (1) placebo + veículo; (2) OVX + veículo; (3) OVX + ZOL (100 g/kg,
dose  única intravenosa); (4) OVX + ZOL (50 g/kg, dose única intravenosa); (5) OVX + PRO
(0,1  mg/kg, via subcutânea, cinco dias por semana); (6) OVX + ZOL (50 g/kg, dose única
intravenosa) + PRO (0,1 mg/kg, via subcutânea, cinco dias por semana) durante 12 semanas.
Depois do tratamento, testou-se a densidade óssea, a porosidade e a microarquitetura tra-
becular dos fêmures. Também foram avaliados marcadores bioquímicos séricos e urinários.
Resultados: A terapia combinada com ZOL mais PRO foi mais eﬁcaz em corrigir a diminuic¸ão
do  cálcio sérico e o aumento do nível sérico de fosfatase alcalina e fosfatase ácida resistente
ao  tartarato do que a monoterapia com ZOL ou PRO. Além disso, a terapia combinada com
ZOL  mais PRO foi mais eﬁcaz em corrigir o aumento dos níveis urinários de cálcio, fósforo e
creatinina do que a monoterapia com ZOL ou PRO. A terapia combinada com ZOL mais PRO
também preservou a microarquitetura trabecular e a porosidade do osso cortical.
Conclusão: Os resultados sugerem que a terapia combinada com ZOL mais PRO pode ser a
abordagem mais eﬁcaz para o tratamento da osteoporose grave em humanos.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
improve the mechanical properties of the spine and femurIntroduction
Osteoporosis is a degenerative disease characterized by
reduced bone mass and deterioration of bone microstructures
which increases the risk of fracture.1 Osteoporosis in most
cases develops without symptoms and has a progressive
course. Timely diagnosis and the selection of ideal therapy
at the appropriate stages of the disease are essential for the
effective treatment and prevention of osteoporosis.
Biochemical markers are emerging as one of the criti-
cal diagnostic tools to screen the bone remodeling during
the progression of bone diseases. They are liberated into
serum and urine as a result of bone formation and bone
resorption and offer an overview of the skeletal health. Apart
from invasive imaging techniques, biochemical markers are
very effective tools for the estimation and are indicative
of various metabolic bone disorders. In contrast to inva-
sive methods like bone mechanical testing’s, the biochemical
markers are convenient to use, inexpensive and non-invasive,
when tested and analyzed correctly, proves to be a potential
tool for the diagnostic and therapeutic determination of bone
disorders.2,3
Zoledronic acid (ZOL) is a third generation nitrogen con-
taining bisphosphonate that has been shown to signiﬁcantly
reduce the risk of fractures in patients who receive the once-
yearly dosing regimen for the treatment of postmenopausal
osteoporosis.4 Although anti-resorptive agents such as bis-
phosphonates are effective in reducing bone loss, they are not
able to induce formation of new bone.1Propranolol (PRO), a non-selective -adrenergic antagonist,
is now considered to be a potential drug under investiga-
tion for fracture healing and more  speciﬁcally for osteoporosis
therapy. In an animal study, a lower dose of PRO, a nonselective
-blocker, has been shown to increase bone mass in different
experimental models of bone disorders.4–10 Results of some
prior epidemiological studies conﬁrm the hypothesis that -
blockers use is associated with a decrease in fracture risk.11–13
Rodrigues et al., demonstrated that PRO suppress bone resorp-
tion by inhibiting osteoclastogenesis as well as inﬂammatory
markers.14 This result is supported by a previous ﬁnding,
which showed that propranolol stimulates osteoprotegerin
(OPG) on its own in osteoblast cells.15 The ability to stimu-
late osteoblast, while also damping osteoclasts makes PRO an
attractive and unique alternative to antiresorptive therapy for
osteoporosis. PRO, which could directly prevent bone loss and
biomechanical alteration by increasing bone formation and
decreasing bone resorption, may be the next anabolic agent
for osteoporosis treatment.4,5,14,15
Combinations of anabolic and antiresorptive agents have
potential to improve bone density and bone strength more
than either agent alone.16 As ovariectomy-induced bone loss
involves both increased bone resorption and decreased bone
formation, it seems obvious to target the ovariectomy-induced
bone loss with a combined anti-resorptive and bone anabolic
treatment regimen, such as ZOL and PRO. We  have previ-
ously shown that the combined ZOL and PRO therapy canand preserves the trabecular microarchitecture in a rat model
of postmenopausal osteoporosis.4 In the light of these results,
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Zr e v b r a s r e u m a t o l
he present study was designed to evaluate further the anti-
steoporotic activity and safety of ZOL and PRO combination
herapy in a rat model of postmenopausal osteoporosis. We
ssessed the parameters as follows: (1) the bone porosity mea-
urement of the right femur; (2) measurement of femoral dry
one weight, volume and density; (3) serum and urine bio-
hemical parameters; and (4) left femurs were used for bone
istopathology.
aterials  and  methods
rugs,  chemicals  and  other  materials
OL was obtained from Naprod Life Sciences, Maharash-
ra, India. PRO, ketamine, xylazine and xylene was obtained
rom Aurobindo Pharma (Hyderabad, India), Glaxo Smithk-
ine Pharmaceuticals (Mumbai, India), Neon Pharma (Mumbai,
ndia), Indian Immunologicals (Hyderabad, India), and S.D.
ine chemicals (Mumbai, India), respectively. Ethicon chromic
utures-3/0, and Ethicon mersilk sutures-3/0 were obtained
rom Johnson & Johnson Ltd., Baddi, Himachal Pradesh,
ndia.
xperimental  animals
n-house laboratory-bred healthy female Wistar rats with 12
eeks age were included for the study. Animals were main-
ained under controlled temperature at 25 ± 2 ◦C with 12 h
ight/dark cycle with food and water and provided ad libitum.
he experiments were conducted as per the CPCSEA (Commit-
ee for the Purpose of Control and Supervision of Experiments
n Animals) guidelines after obtaining ethical clearance from
he Institutional Animal Ethical Committee.
re-clinical  study  design
t three months of age, ovariectomy was performed under
etamine and xylazine anesthesia (80 and 10 mg/kg; i.p.)
ccording to the method described by Khajuria et al.17 The
HAM-operation rats were subject to SHAM surgery exposure
ithout removing the ovaries. At 3 months after ovariec-
omy (age: 6 months), animals were divided into six groups
f six animals each. A group of ovariectomized (OVX) rats
as left untreated (untreated OVX). Both the untreated OVX
nd the sham OVX groups were used as controls. Two OVX
roups were treated with single intravenous dose of ZOL at
0 g/kg (ZOL 50 group) and 100 g/kg (ZOL 100 group), admin-
stered into tail vein as a slow intravenous injection over 30 s
nder light inhalation anesthesia. One OVX group was treated
ith PRO at a dose of 0.1 mg/kg, injected subcutaneously 5
ays per week, for 12 weeks. Treatment on the remaining
VX group was initiated with a 50 g/kg ZOL and 0.1 mg/kg
RO combination-treated (ZOL 50 + PRO) group. Subcutaneous
njections ﬁve days per week in case of OVX groups treated
ith PRO and ZOL 50 + PRO require some animal handling and
reate some stress to the animals. Therefore, apart from pos-
tive and negative control groups, OVX groups treated with
OL (100 and 50 g/kg, intravenous single dose) were also 5;5 5(2):103–112 105
subcutaneously administered vehicle (normal saline, 5 days
per week) for 12 weeks. The medication dosages used in this
experiment were selected from previous studies on rat osteo-
porosis model.4
At the end of an experiment (animals aged approximately 9
months), rats were anesthetized with ether and blood was col-
lected from retro-orbital plexus. After, centrifugation serum
was harvested and kept at −20 ◦C until analysis. At the end
of the study, all groups were euthanized by an overdose of
anesthesia. In all rats, femurs were excised and cleared of fat
and connective tissues. Right femurs were soaked in saline
solution gauze and frozen at −20 ◦C for the bone porosity and
density tests. In all rats, left femurs were excised and cleared
of fat and connective tissues, and immediately ﬁxed in 10%
formaldehyde for 48 h at 4 ◦C.
Serum  and  urine  biochemical  analysis
The levels of serum and urine calcium, serum and urine
inorganic phosphorous, urine creatinine and alkaline phos-
phatase activity were estimated by commercially available
kits (Autospan, Span diagnostics Ltd., Surat, India) using
autoanalyzer (Artos semi-autoanalyzer, Swemed Biomedicals
Pvt. Ltd., Bangalore, India). Serum tartarate resistant acid
phosphatase (TRAP) activity was determined by a nitrophenol-
based method as described by Janckila et al.18
Measurement  of  bone  porosity  by  X-ray  imaging
The right femurs of all animals were scanned with foX-Rayzor,
which is a portable X-ray inspection system equipped with
“Calculate histogram” tool software, according to the method
described by Khajuria et al.6 Brieﬂy, for X-ray analysis, whole
femur was divided into four equal ﬁelds, which includes distal
femoral epiphysis (R1), femoral shaft (R2 and R3) and proximal
femur (R4).
Measurement  of  dry  bone  weight,  volume  and  density
After X-ray, the right femur of all animals was dehydrated
with ethanol, and fat was removed with diethyl ether. After
the bones were allowed to air-dry, the dry bone weight was
measured with a digital weighing balance (Contech CA-124,
Contech Instuments Ltd., Mumbai, India). The volume and
density of the bones were measured according to the proce-
dure reported by Khajuria et al.6
Bone  histopathology
The left femurs were cleaned from soft tissue, placed in decal-
cifying solution [8% hydrochloric acid (37%, v/v) and 10%
formic acid (89%, v/v) in phosphate-buffered saline] for about
24 h at 37 ◦C, dehydrated in 95% (v/v) ethanol and embedded in
parafﬁn. 5 mm-thick parafﬁn-embedded horizontal bone sec-
tions were cut from the proximal end of the diaphysis, stained
with hematoxylin–eosin and examined by light microscopy.
Femur heads (the area between the hip joint cartilage and
metaphyseal cartilage) were assessed for the quality of bone
and trabecular density, according to the score shown in Table 1.
Cartilage integrity is considered as an additional index of
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Table 1 – Criteria for the evaluation of the histopathological score used to assess the degree of osteoporosis.
Score Hip joint cartilage integrity Structure of
trabecular bone
Quantity of trabecular
bone (% of interest area)
0 Cartilage complete Normal 90–100
1 Cartilage complete Partially reduced 60–90
2 Cartilage partially complete 
3 Cartilage absent 
bone quality, because osteoporosis is also responsible for car-
tilage deterioration and treatments that restore bone integrity
are also able to preserve a good trophism of the cartilage
indirectly.19
Safety  assessment  of  different  treatments
General toxicity study was conducted in accordance with good
laboratory practices (GLP) and the OECD (Organization for
Economic Co-operation and Development) guidelines for the
Testing of Chemicals with some modiﬁcations. Changes in
behavior, physical parameters (body weight, food and water
intake) and local injury (tissue damage or necrosis at site of
injection, inﬂammation and any other abnormal signs) were
studied throughout the treatment period. Mortality if any,
in all the groups, during the course of treatment was also
recorded. At the end of treatment hematological, biochemi-
cal (liver function tests and renal function tests) were studied.
Serum biochemistries were analyzed with a semi automated
chemistry analyzer using kits for serum glutamic oxaloacetic
transaminase (SGOT) and serum glutamic pyruvate transam-
inase (SGPT) from Agappe Diagnostics Ltd., Kerala, India.
Other parameters were estimated such as blood urea nitrogen
(Autospan, Span Diagnostics Ltd., Surat, India), total protein
and creatinine (Agappe Diagnostics Ltd., Kerala, India) as signs
of nephrotoxicity.
Statistical  analysisAll data were expressed as the mean ± standard deviation (SD).
For all the data, comparisons between different treatments
were analyzed by one-way ANOVA followed by Tukey’s mul-
tiple comparison tests. In all cases, a probability error of less
Table 2 – Effects of zoledronic acid and propranolol, alone or in
phosphorous (Pi), alkaline phosphatase (ALP) and tartarate resi
Group Ca (mg/dL) Pi (mg/dL) 
SHAM 9.03 ± 0.13a 6.77 ± 0.41 
OVX 7.99 ± 0.29 6.30 ± 0.38 
OVX + ZOL 100 8.03 ± 0.58 6.43 ± 0.25 
OVX + ZOL 50 8.31 ± 0.51 6.55 ± 0.42 
OVX + PRO 8.11 ± 0.21 6.53 ± 0.44 
OVX + ZOL 50 + PRO 9.13 ± 0.82a 6.90 ± 0.32 
Data are shown as the mean ± SD (n = 6), evaluated by Tukey’s multiple com
a p < 0.05.
b p < 0.01.
c p < 0.001, compared to OVX group.
d p < 0.05, compared to ZOL 50 + PRO group.
All groups except SHAM group undergo ovariectomy.Markedly reduced 30–60
Absent 0–30
than 0.05 was selected as the criterion for statistical signiﬁ-
cance. Graphs were drawn using Graph Pad Prism (version 5.0
for Windows).
Results
Effects  on  serum  biochemical  parameters
Serum calcium concentration was signiﬁcantly lower in the
OVX group than in the SHAM group (p < 0.05). Signiﬁcant dif-
ferences were not observed in the single treatment groups
relative to the OVX group. However, the serum calcium level
in the ZOL 50 + PRO group was signiﬁcantly higher than that
in the OVX group (p < 0.05). The ﬁnal serum phosphorus lev-
els were not signiﬁcantly different between the SHAM and the
OVX animals. Likewise, there were no changes in the serum
phosphorous levels observed among the several pharmacolog-
ical treatments (Table 2).
At the end of experiment, serum level of alkaline phos-
phatase was signiﬁcantly higher in the OVX group than in the
SHAM group (p < 0.001). In contrast, the serum level of alkaline
phosphatase was signiﬁcantly lower in all single treatment
groups as compared to OVX group (p < 0.05). Likewise, the
serum alkaline phosphatase level in the ZOL 50 + PRO group
was signiﬁcantly lower than that in the OVX group (p < 0.01).
Moreover, the serum alkaline phosphatase levels in the ZOL
50 + PRO group were signiﬁcantly lower than those in the ZOL
100, ZOL 50 and PRO groups (p < 0.05, Table 2). Ovariectomy
induced high bone turnover in rats and increased serum TRAP
levels in the OVX control group in comparison with the SHAM
control group (p < 0.001). The ZOL 100, ZOL 50, PRO and ZOL
50 + PRO groups had signiﬁcantly decreased serum TRAP lev-
els compared to the OVX group (p < 0.01, p < 0.001, p < 0.001 and
 combination on serum calcium (Ca), inorganic
stant acid phosphatase (TRAP) levels in OVX rats.
ALP (IU/L) TRAP (U/L)
74.85 ± 3.88c 0.31 ± 3.02c
155.7 ± 14.47 1.18 ± 10.12
108.2 ± 9.65b,d 0.72 ± 9.05b,d
105.01 ± 8.13b,d 0.66 ± 10.18c,d
103.36 ± 6.14b,d 0.63 ± 14.99c,d
80.03 ± 10.13c 0.41 ± 10.1c
parison test.
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Table 3 – Effects of zoledronic acid and propranolol, alone or in combination on urine calcium (Ca), inorganic
phosphorous (Pi) and creatinine (Cr) levels in OVX rats.
Group Ca (mg/dL) Pi (mg/dL) Creatinine (mg/dL)
SHAM 20.10 ± 7.16c 3.86 ± 0.33c 1.22 ± 0.81c
OVX 48.33 ± 11.07 5.58 ± 0.88 3.14 ± 0.97
OVX + ZOL 100 34.03 ± 17.58a,d 4.36 ± 0.56a,d 1.82 ± 0.49b,d
OVX + ZOL 50 36.31 ± 11.98a,d 4.15 ± 0.59a,d 1.67 ± 0.46b,d
OVX + PRO 33.22 ± 12.81a,d 4.05 ± 0.74a,d 1.76 ± 0.39b,d
OVX + ZOL 50 + PRO 28.15 ± 9.02c 3.68 ± 0.42c 1.13 ± 0.34c
Data are shown as the mean ± SD (n = 6), evaluated by Tukey’s multiple comparison test.
a p < 0.05.
b p < 0.01.
c p < 0.001, compared to OVX group.
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All groups except SHAM group undergo ovariectomy.
 < 0.001, respectively). Moreover, signiﬁcant reductions in lev-
ls of serum TRAP levels were observed in the ZOL 50 + PRO
roup compared to the ZOL 100, ZOL 50 and PRO groups
p < 0.05).
ffects  on  urinary  calcium,  phosphorous  and  creatinine
evels
he urinary calcium, phosphorous and creatinine excre-
ion proﬁles of the SHAM group, OVX group and OVX rats
reated with various therapeutic interventions are shown in
able 3. A signiﬁcant increase in urinary calcium excretion was
bserved in the OVX control in comparison to the SHAM group
p < 0.001). The ZOL 100, ZOL 50, PRO and ZOL 50 + PRO groups
ad signiﬁcantly decreased urinary calcium excretion (p < 0.01,
 < 0.01, p < 0.01 and p < 0.001, respectively). Similarly, a signiﬁ-
ant increase in urinary phosphorous excretion was observed
n the OVX control compared to the SHAM group (p < 0.001).
he ZOL 100, ZOL 50, PRO and ZOL 50 + PRO groups had sig-
iﬁcantly decreased urinary phosphorous excretion (p < 0.01,
 < 0.01, p < 0.01 and p < 0.001, respectively). Likewise, a signiﬁ-
ant increase in urinary creatinine excretion was observed in
he OVX control in comparison to the SHAM group (p < 0.001).
he ZOL 100, ZOL 50, PRO and ZOL50 + PRO groups had sig-
iﬁcantly decreased urinary creatinine excretion (p < 0.01,
 < 0.01, p < 0.01 and p < 0.001, respectively). Moreover, signiﬁ-
ant reductions in the levels of urine calcium, phosphorous
nd creatinine were observed in the ZOL 50 + PRO group
ompared to the ZOL 100, ZOL 50 and PRO groups (p < 0.05;
able 3).
easurement  of  dry  bone  weight,  volume  and  density
able 4 summarizes the effects of OVX and treatment of OVX
ats with ZOL 100, ZOL 50, PRO and ZOL 50 + PRO groups
n dry bone weight, volume and the dry bone weight per
one volume (density) of the right femur. Dry bone weight of
VX control animals was found to be signiﬁcantly less than
HAM control animals (p < 0.001). ZOL 100, ZOL 50 and PRO
roups exhibited higher values for dry bone weight than the
VX group (p < 0.05, p < 0.01 and p < 0.01, respectively). Simi-
arly, ZOL 50 + PRO group exhibited higher values for dry bone
eight than the OVX group (p < 0.001). The bone volume offemur in the OVX group was signiﬁcantly higher than that in
the SHAM group (p < 0.05). This conclusion is based on the gain
in body weight observed in the OVX group. No signiﬁcant dif-
ferences were observed in the bone volume of all therapeutic
interventions as compared to the OVX group (Table 4). With
respect to bone mass, the OVX group exhibited signiﬁcantly
lower values for density of the femur than did the SHAM group
animals (p < 0.001). This indicates that the bone mass density
is decreased by ovariectomy. Values in both bisphosphonate
groups (ZOL 100 and ZOL 50) and PRO group were higher than
those in the OVX group (p < 0.01, p < 0.001 and p < 0.001, respec-
tively). Similarly, the values were signiﬁcantly higher in the
ZOL 50 + PRO group as compared to the OVX group (p < 0.001).
The dry bone weight and density in the ZOL 50 + PRO group
were signiﬁcantly higher than that in the ZOL 100, ZOL 50 and
PRO groups (p < 0.05).
Bone  porosity
The effects of OVX and subsequent treatment with ZOL 100,
ZOL 50, PRO and ZOL 50 + PRO groups on the porosity of the
right femur were measured by X-ray imaging. X-ray transmis-
sion intensity for the OVX group at R1 (distal epiphysis), R2
(mid-shaft: distal), R3 (mid-shaft: proximal), and R4 (proximal
epiphysis) was signiﬁcantly higher than those for the SHAM
group, which indicates an OVX-elicited increase in porosity
in these areas. After 12 weeks of therapy, all the active treat-
ments succeeded in decreasing bone porosity in OVX animals.
X-ray transmission intensity values at R1 for ZOL 100, ZOL 50,
PRO and ZOL 50 + PRO groups were lower than those of OVX
group (p < 0.05, p < 0.01, p < 0.01 and p < 0.001, respectively). The
X-ray transmission intensity of the ZOL 50 + PRO group was
signiﬁcantly lower than that of the ZOL 100, ZOL 50, and PRO
groups at R1 (p < 0.01, p < 0.05 and p < 0.05, respectively). More-
over, the X-ray transmission intensity values at R2, R3 and R4
regions for ZOL 100, ZOL 50, PRO and ZOL 50 + PRO groups were
lower than those of OVX group (p < 0.05, p < 0.05, p < 0.05 and
p < 0.001, respectively). The X-ray transmission intensity of the
ZOL 50 + PRO group was signiﬁcantly lower than that of all sin-
gle treatments at R2, R3 and R4 region (p < 0.05). No signiﬁcant
differences were observed among single treatment groups at
R1, R2, R3 and R4 regions. These results indicate that the com-
bined treatment with ZOL 50 + PRO is beneﬁcial for the mass
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Table 4 – Effects of zoledronic acid and propranolol, alone or in combination on dry bone weight, volume and density in
OVX rats.
Group Dry weight (mg) Volume (mL) Density (g/mL)
SHAM 615.2 ± 26.20b 0.31 ± 0.03a 1.98 ± 0.02c
OVX 488.7 ± 25.20 0.37 ± 0.04 1.31 ± 0.05
OVX + ZOL 100 601.6 ± 33.40a,d 0.37 ± 0.03 1.63 ± 0.03c,d
OVX + ZOL 50 626.6 ± 20.90b,d 0.37 ± 0.02 1.69 ± 0.04c,d
OVX + PRO 630.7 ± 19.40b,d 0.36 ± 0.04 1.75 ± 0.03c,d
OVX + ZOL 50 + PRO 674.2 ± 22.30c 0.35 ± 0.03 1.90 ± 0.06c
Data are expressed as the mean ± SD (n = 6), evaluated by one-way ANOVA followed by Tukey’s multiple comparison test.
a p < 0.05.
b p < 0.01.
c p < 0.001, compared to OVX group.
roupd p < 0.05, compared to ZOL 50 + PRO group.All groups except SHAM g
of both trabecular and cortical bones that were decreased by
OVX (Fig. 1).
Effect  of  the  treatments  on  bone  histopathologyThe sections of the femur head were examined for any
histopathological changes. The animals of the SHAM group
showed normal compactness of the diaphysis and compe-
tent trabeculae (Fig. 2a). The OVX animals showed sparse,
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Fig. 1 – Effect of zoledronic acid and propranolol, alone or in com
porosity of R1: distal femoral epiphysis (panel a), R2: distal femo
proximal femoral epiphysis (panel d). Data are shown as the me
test. *p < 0.05; **p < 0.01; ***p < 0.001, compared to OVX group; ap < undergo ovariectomy.
uniform thinning of the trabeculae with tendency of dis-
appearance and loss of connectivity resulting in widened
intertrabecular spaces (Fig. 2b). Cartilaginous proliferates in
the area of softened plates of focal to restricted islets were
also observed. Bone histopathology (Fig. 2c–f) revealed a
marked effect of ZOL 100, ZOL 50, PRO and ZOL 50 + PRO
in ovariectomy-induced osteoporosis. The histological score
(Fig. 3) of all groups evaluated following the criteria is shown in
Table 1. Histopathological assessment of animals treated with
all therapeutic interventions showed a restored architecture
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bination on femoral porosity of ovariectomized rats. Bone
ral shaft (panel b), R3: proximal femoral shaft (panel c), R4:
an ± SD (n = 6), evaluated by Tukey’s multiple comparison
 0.05; bp < 0.01, compared to ZOL + PRO group.
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Fig. 2 – Effect of zoledronic acid and propranolol, alone or in combination on the femoral trabecular micro architecture in
ovariectomized rats: (a) SHAM group; (b) OVX group; (c) OVX + ZOL 100 group; (d) OVX + ZOL 50 group; (e) OVX + PRO group;
and (f) OVX + ZOL 50 + PRO group. H&E staining; scale bar = 100 m.  Images are taken at magniﬁcation 50×.
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ig. 3 – Effect of zoledronic acid and propranolol, alone or in
ombination on the histopathological score. Data are
hown as the mean ± SD (n = 6), evaluated by Tukey’s
ultiple comparison test. ***p < 0.001, compared to OVX
roup. All groups except SHAM group undergo ovariectomy.of cortical and trabecular bone with well-organized bone
matrix.
Safety  assessment
All follow-up animals survived during the study period. In
addition, no adverse clinical signs or symptoms were observed
during the experimental period. There were no signiﬁcant dif-
ferences in food and water consumption between control and
treated groups (data not shown). No signiﬁcant differences in
body weights between OVX controls and treated groups were
observed during the study period (data not shown). No signif-
icant differences in hematological parameters were detected;
hemoglobin, total erythrocyte count and total leukocyte count
were similar across all treatment groups (Table 5).
There were no signiﬁcant changes observed in serum total
protein, creatinine and blood urea nitrogen levels in all single
and combined treatment groups when compared to control
group. No signiﬁcant increases were observed in serum SGPT
and SGOT levels in all therapeutic interventions when com-
pared to control group (Table 6).
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Table 5 – Effects of zoledronic acid and propranolol, alone or in combination on various biochemical parameters in OVX
rats.
Group Hemoglobin (g %) Total RBC (×106/mm3) Total WBC (×103/mm3)
SHAM 15.17 ± 1.42 5.98 ± 0.89 5.92 ± 0.96
OVX 13.98 ± 1.96 5.87 ± 0.97 5.81 ± 1.11
OVX + ZOL 100 14.44 ± 2.11 6.12 ± 1.13 6.09 ± 1.22
OVX + ZOL 50 14.85 ± 2.01 5.73 ± 0.68 5.89 ± 0.50
OVX + PRO 15.01 ± 1.63 5.83 ± 1.17 5.77 ± 0.88
OVX + ZOL 50 + PRO 14.11 ± 1.36 5.79 ± 0.70 5.97 ± 1.09
Data are expressed as the mean ± SD (n = 6). All groups except SHAM group undergo ovariectomy.
Table 6 – Effects of zoledronic acid and propranolol, alone or in combination on total serum protein, creatinine, blood
urea nitrogen, serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvate transaminase (SGPT).
Group Total serum
protein (g/dL)
Creatinine
(mg/dL)
Blood  urea
nitrogen (mg/dL)
SGPT (U/L) SGOT (U/L)
SHAM 6.90 ± 0.18 0.66 ± 0.01 18.03 ± 1.42 24.81 ± 1.70 34.76 ± 1.45
OVX 6.17 ± 0.04 0.73 ± 0.03 17.73 ± 2.09 25.63 ± 1.67 33.22 ± 1.78
OVX + ZOL 100 6.32 ± 0.15 0.71 ± 0.01 17.38 ± 0.95 24.25 ± 1.71 33.19 ± 2.25
OVX + ZOL 50 6.03 ± 0.67 0.69 ± 0.01 16.45 ± 3.64 23.49 ± 2.80 32.17 ± 2.85
OVX + PRO 6.47 ± 0.13 0.73 ± 0.01 
OVX + ZOL 50 + PRO 6.41 ± 0.12 0.74 ± 0.04 
Discussion
The results of the present preclinical study clearly show that
ZOL plus PRO combination therapy was able to counteract
the bone loss in a rat model of postmenopausal osteoporo-
sis. These ﬁndings support our previous research indicating
that the addition of PRO to antiresorptive therapy with ZOL is
clearly superior to either intervention alone.4
It is established that the rate of bone loss after estrogen
deﬁciency may be indirectly assessed with the use of estab-
lished biochemical markers of bone turnover.20 Reduction in
bone mass, altered calcium metabolism and signiﬁcant lower
values of serum calcium level had been reported in the post-
menopausal women.21,22 In this study, combination treatment
with ZOL plus PRO completely corrected the decrease in serum
calcium levels, indicating that the combination therapy ame-
liorated the changes in calcium.
ZOL plus PRO group was statistically superior in decreasing
the serum alkaline phosphatase in the OVX rats. Moreover,
combined treatment with ZOL plus PRO was statistically supe-
rior to all single treatments in suppressing the increase in
serum amounts of TRAP. These results suggest that ZOL plus
PRO treatment ameliorated the bone loss due to ovariec-
tomy by both stimulation of bone formation and inhibition
of bone resorption. Fast bone losers have elevated concen-
trations of bone resorption markers, compared with slow
bone losers.23 OVX rats in the present study had an increase
loss of urinary calcium, phosphorous and creatinine levels,
compared to the SHAM group. But these responses were sig-
niﬁcantly lowered in OVX rats on receiving ZOL plus PRO
therapy. This suggests that this signiﬁcant decrease in urinary
excretion of calcium, phosphorous and creatinine levels could
be attributed to decreased bone resorption and/or increased
bone formation or both. It is noteworthy to mention that
combined treatment with ZOL plus PRO was statistically18.60 ± 2.42 25.15 ± 1.46 34.80 ± 3.48
18.84 ± 2.88 25.27 ± 2.70 33.81 ± 0.44
superior to all other therapeutic interventions in suppressing
the increase in urinary amounts of calcium, phosphorous and
creatinine.
In the analysis of the bone porosity of rat femur using X-
ray imaging, it was found that combined therapy with ZOL
plus PRO was statistically superior to ZOL or PRO monotherapy
in suppressing the increase in bone porosity, which is due to
ovariectomy. This indicates that combined therapy with ZOL
plus PRO thickens and strengthens cortical bone. The results of
the femoral dry weight and density values estimated directly
were consistent with those on femoral porosity found by X-
ray imaging. In this study, OVX animals showed a signiﬁcant
decrease in femoral dry weight and density similar to those
seen in estrogen deﬁcient osteoporotic women. It is interesting
to note that, in animals treated with single and combined ther-
apy, femoral dry weight and density values were signiﬁcantly
greater than those of the OVX group. Moreover, in the ani-
mals treated with combined therapy of ZOL plus PRO, femoral
dry weight and density values were signiﬁcantly greater than
those of the ZOL or PRO groups. These results showed that
the combined treatment with ZOL plus PRO is beneﬁcial for
increasing the mass of rat femoral bones that was decreased
due to ovariectomy.
Bone histopathology analysis of the OVX rats showed
decrease in number and thickness of trabecular and widened
intra-trabecular spaces suggesting that bone loss was induced
in OVX rats by decreasing bone formation and increasing bone
resorption. Histopathological examination also revealed the
anti-osteoporotic property of combination therapy as demon-
strated by the restoration of trabecular bone in ZOL plus PRO
treated group compared with the OVX group. As an outcome,
the combined therapy with ZOL plus PRO may act both on col-
lagen structure and bone resorption. This in turn may reduce
non-vertebral fractures (example hip fracture), which are the
most clinically relevant type of fracture in the elderly popula-
tion.
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Testing for general toxicity using appropriate models can
elp to deﬁne risks of adverse events and to design clini-
al monitoring protocols with clear endpoints. To investigate
ossible toxic outcomes of single and combined treatments,
hysical, hematological and biochemical parameters were
stimated. There were no signs of toxicity observed at any dose
evel of all therapeutic interventions used in this study. No
ortality was seen in any of the treatment groups. Hematolog-
cal and biochemical parameters were unaltered at all single
nd combined dose levels of treated groups as compared to
ontrol. It was inferred from results of our study that the ZOL
nd PRO as a monotherapy and combination therapy are non-
oxic to experimental animals. The present study has proven
he safety proﬁle of single and combined therapies used for
reatment of osteoporosis.
onclusions
he result of the present investigation demonstrates that
ombination therapy using ZOL (antiresorptive agent) and PRO
anabolic agent) may represent a powerful novel approach
or treating or reversing severe osteoporosis in humans. As
uch, this combined regimen can be of interest for further
valuation in clinical studies to represent a potentially useful
herapeutic option for patients with osteoporosis. Moreover,
RO might be a new potential bone anabolic agent for preven-
ion/treatment of osteoporosis, and it can be used either alone
r in conjunction with bisphosphonate drugs.
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